Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlimid Rivals Debut In Canada

Lenalidomide Launches By Dr Reddy’s And Natco Follow Settlements With Celgene

Executive Summary

Dr Reddy’s and Natco have announced launches of Canadian rivals to Celgene’s Revlimid, with lenalidomide capsules from both companies made available from the start of September following settlements with the originator.

You may also be interested in...



Biogen Launches Lucentis Biosimilar Byooviz In Canada

Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.

Dr Reddy’s Must Notify Celgene Of Plans To Sell Revlimid Generic In Australia

Australia’s Federal Court has ordered Dr Reddy’s to provide Celgene with three months written notice that it intends to bring a generic lenalidomide Revlimid rival to market.

Dr Reddy’s Eyes Generic Revlimid Exclusivity With ANDA Approval

With Natco poised to debut the first batch of Revlimid generics in the US in March next year, fellow Indian ANDA sponsor Dr Reddy’s Laboratories has secured its own approval from the FDA for two strengths of the blockbuster multiple myeloma treatment.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel